PPARα/γ agonist 5

• UNSPSC Description:

  PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC50 of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy[1].

• Target Antigen:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pparα-γ-agonist-5.html

• Smiles:

  OC([C@H](OC)CC1=C2C(C=CS2)=C(C=C1)OCCC3=C(C)OC(C4=CC=CC=C4)=N3)=O

• Molecular Weight:

  437.51

• References & Citations:

  [1]Aleglitazar, a new, potent, and balanced dual PPARa/c agonist for the treatment of type II diabetes

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  849150-59-0